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Abstract: Anemia is a common finding in lymphoma. There are few data available regarding the 
erythropoietin (EPO) levels in conjunction with ferritin in lymphoma patients. We prospectively 
evaluated 55 patients diagnosed with malignant lymphoma during the peri
2006  and  March  2008  at  the  King  Abdullah  University  Teaching  Hospital,  Jordan.  Our  data 
showed  that 74.4%  of lymphoma patients  were  anemic.  Furthermore,  serum  EPO  and  ferritin 
levels  were  higher  in  lymphoma  patients  compared  with  the  he
observed versus predicted EPO ratio showed also significantly higher levels in anemic lymphoma 
patients  compared  to  healthy  controls  (p=0.03).  There  was  an  improvement in 
lymphoma patients who were treated with
newly-diagnosed patients. An adequate increase of EPO levels was observed in anemic lymphoma 
patients and notably associated with higher ferritin levels and improvement of Hb (p<0.001).
Our  findings  suggest  that  ferritin  estimation  in  lymphoma  patients  may  predict  the  level  of 
erythropoiesis and possibly the degree of anemia. Further studies to confirm these findings are 
warranted. 
Introduction: Anemia  is  common  in  patients  with 
cancer, especially Hodgkin’s lymphoma (HL) and non
Hodgkin’s  lymphomas  (NHL).
1,2  About  30
lymphoma  patients  present  with  anemia
commencement  of  chemotherapy.  The  anemia  is 
mainly  attributed  to  bone  marrow  replacement  by 
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Anemia is a common finding in lymphoma. There are few data available regarding the 
erythropoietin (EPO) levels in conjunction with ferritin in lymphoma patients. We prospectively 
evaluated 55 patients diagnosed with malignant lymphoma during the peri
King  Abdullah  University  Teaching  Hospital,  Jordan.  Our  data 
showed  that 74.4%  of lymphoma patients  were  anemic.  Furthermore,  serum  EPO  and  ferritin 
levels  were  higher  in  lymphoma  patients  compared  with  the  healthy  controls  (P=0.001).  The 
observed versus predicted EPO ratio showed also significantly higher levels in anemic lymphoma 
patients  compared  to  healthy  controls  (p=0.03).  There  was  an  improvement in 
lymphoma patients who were treated with at least 3-cycles of chemotherapy as compared with 
diagnosed patients. An adequate increase of EPO levels was observed in anemic lymphoma 
patients and notably associated with higher ferritin levels and improvement of Hb (p<0.001).
Our  findings  suggest  that  ferritin  estimation  in  lymphoma  patients  may  predict  the  level  of 
erythropoiesis and possibly the degree of anemia. Further studies to confirm these findings are 
Anemia  is  common  in  patients  with 
cancer, especially Hodgkin’s lymphoma (HL) and non-
About  30-40  %  of 
lymphoma  patients  present  with  anemia prior  to 
commencement  of  chemotherapy.  The  anemia  is 
mainly  attributed  to  bone  marrow  replacement  by 
lymphoma  cells  or  inadequate  erythropoietin  (EPO) 
production which leads to  suppressed erythropoiesis.
The frequency of anemia increases in all malignan
with the largest increase in patients with NHL (from 
35.1% at baseline to 73.7%) and HL (from 21.9% to 
54.5%)  under  the  age  of  60.
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Anemia is a common finding in lymphoma. There are few data available regarding the 
erythropoietin (EPO) levels in conjunction with ferritin in lymphoma patients. We prospectively 
evaluated 55 patients diagnosed with malignant lymphoma during the period between November 
King  Abdullah  University  Teaching  Hospital,  Jordan.  Our  data 
showed  that 74.4%  of lymphoma patients  were  anemic.  Furthermore,  serum  EPO  and  ferritin 
althy  controls  (P=0.001).  The 
observed versus predicted EPO ratio showed also significantly higher levels in anemic lymphoma 
patients  compared  to  healthy  controls  (p=0.03).  There  was  an  improvement in  the  Hb  level in 
cycles of chemotherapy as compared with 
diagnosed patients. An adequate increase of EPO levels was observed in anemic lymphoma 
patients and notably associated with higher ferritin levels and improvement of Hb (p<0.001).
Our  findings  suggest  that  ferritin  estimation  in  lymphoma  patients  may  predict  the  level  of 
erythropoiesis and possibly the degree of anemia. Further studies to confirm these findings are 
lymphoma  cells  or  inadequate  erythropoietin  (EPO) 
production which leads to  suppressed erythropoiesis.
3 
The frequency of anemia increases in all malignancies, 
with the largest increase in patients with NHL (from 
35.1% at baseline to 73.7%) and HL (from 21.9% to 
54.5%)  under  the  age  of  60.
4-6 EPO  stimulates  the Mediterr J Hematol Infect Dis 2011, 3; Open Journal System
proliferation and maturation of erythroid precursors in 
the bone marrow. The earliest progenitor form that can 
be identified is the erythroid burst-forming unit (BFU-
E), which subsequently evolve into erythroid colony-
forming units (CFU-E). EPO acts primarily on these 
cells  by  stimulating  cell  division  and  maturation  as 
well as inhibiting apoptosis.
7 Tissue hypoxia triggers 
endogenous  EPO  production  when  hemoglobin  (Hb) 
falls below 12 g/dL.
8,9   When hypoxia resolves, EPO 
production decreases.
9
Initial  studies  in  patients  with  cancer  found  that 
most of the patients had disproportionately low levels 
of  endogenous  EPO  for  the  degree  of  their  anemia, 
especially  after  chemotherapy.
10-12  Some  studies 
showed that cancer-related anemia patients had serum 
EPO levels above the normal range which shows their 
strong ability into self-body regulation in response to 
anemia.
10-12 Although some studies suggested that EPO 
levels decrease in malignant lymphoma,
11,13  however, 
others  reported  that  EPO  levels  increase  in  anemic 
lymphoma  patients,  indicating  that  anemia  did  not 
depend  on  defective  EPO  secretion.
14 Ferritin  is 
synthesised and released from malignant lymphocytes 
in  a faster manner than  normal  lymphocytes causing 
ferritin concentration to increase in those patients.
15-17
However, there is very few studies that address EPO 
response  in  association  with  ferritin  levels  in 
conjunction  with  anemia  response  in  malignant 
lymphoma. The aims of our study were to determine 
(a) the EPO and ferritin levels in de novo and treated 
lymphoma  patients,  and  (b)  whether  there  is  a 
relationship between EPO level and ferritin response to 
anemia. 
Patients and Methods: Fifty-five serum samples were 
obtained  from  patients  who  were  diagnosed  with 
malignant lymphomas (29 HL and 26 NHL) during the 
period between November 2006 to March 2008 at the 
King Abdullah University Teaching Hospital. Written 
consent was obtained from all patients. This study was 
ethically approved by the Conjoint Ethics Committee 
of  Jordan  University  of  Science  and  Technology. 
Thirty  samples  were  obtained  from  newly-diagnosed 
patients  and  twenty-five  from  patients  who  were 
receiving  chemotherapy  after  at  least  3  cycles  of 
chemotherapy. Both groups included anemic and non-
anemic patients. The specific diagnosis and the stage of 
the disease for each lymphoma patient were obtained 
from patients clinical notes. We included in the study 
newly  diagnosed  patients  with  malignant  lymphoma 
and patients who had received at least three cycles of 
chemotherapy  for  malignant  lymphoma  and  had  not 
received blood transfusions for at least 12 weeks. 
There were an equal number of samples collected at 
the  time  of  diagnosis  and  after  3  cycles  of 
chemotherapy. Bone  marrow studies  were performed 
for  all  patients  and  showed  that  13  cases  had  bone 
marrow  involvement  (stage  IV  lymphoma  disease) 
without a significant compromise of the hemopoeitic
reserve. 
We  excluded  patients  with  hepatitis,  infections, 
liver  disease,  renal  failure,  iron,  B12  and  folate 
deficiencies  and  patients  with  hemolytic  anemia  as 
these conditions may influence the levels of ferritin and 
EPO. Infections markers were negative for the patients 
included  in  the  study.  Furthermore,  no  patients 
received erythropoietin therapy in this study.
Fifty-five healthy, sex and age-matched volunteers 
were randomly selected as a control group. All control 
group participants provided a written consent. 
Non-fasting 5-10 ml serum samples were obtained 
from  all  participants  during  the  morning  at  room 
temperature.  Samples  were  centrifuged  within  30 
minutes of collection at 2000 rpm for 10 minutes at 
room  temperature  and  sera  were  isolated  from  each 
sample.  For  each  patient,  the  following  tests  were 
performed:  serum  EPO,  Hb,  creatinine,  lactate 
dehydrogenase (LDH), B12, folate and ferritin. Serum 
vitamin  B12  was  obtained  to  exclude  megaloblastic 
anemia. EPO was measured by ELISA (IBL-Hamburg 
kit,  Germany).  Ferritin  levels  were  measured  by 
electrochemiluminescence  immunoassay  (ECLIA) 
using an Elecsys 1020-immunoassay analyzer (Roche
Diagnostics, Indianapolis, Indiana, USA). 
Definitions: Stage A lymphoma disease is defined by 
absence  of  constitutional  symptoms,  while  stage  B 
means presence of B-constitutional symptoms such as 
weight loss, night sweats or fever.  
Stage  I-II  lymphoma  represent  a  localized  nodal 
disease, while stage III lymphoma disease represents
wide-speared nodal disease but with absence of non-
reticuloendothelial  organ  involvement,  and  stage  IV 
lymphoma disease reflects organ involvement such as 
bone marrow, liver or lung involvement. Extra-nodal 
disease is defined as involvement of other organs that 
are  not  related  to  the  reticulo-endothelial  system. 
Severe  anemia  is  defined by  a  level  of  Hb  <8  g/dl, 
while moderate anemia; Hb=8-10 g/dl and mild anemia 
in  males;  Hb=10-13  g/dl  and  in  females;  Hb=10-12 
g/dl. 
Statistical  analysis: Means, standard  deviations (SD) 
and difference of means were estimated for illustrative 
purposes using general linear modelling. Assumptions 
of  linear  regression  were  violated  in  most  of  these 
analyses  due  to  heteroskedasticity  and  skewness  of 
residuals;  therefore,  non-parametric  analyses  (ordinal 
logistic regression) were performed to test differences 
of distributions. P-values were corrected for multiple Mediterr J Hematol Infect Dis 2011, 3; Open Journal System
Table 1. Characteristics and laboratory results of the patients and healthy controls
EPO, serum erythropoietin. Hb, hemoglobin. Mean (SD), and difference estimated by general linear modeling for illustrative purposes, and 
comparison tested using Mann-Whitney rank-order test due to non-normal distributions. O/P, observed/predicted EPO ratio after adjustment 
for endogenous EPO response from the normal EPO production/activity.
comparisons where appropriate by the Holm method. 
All statistical analyses were performed using Stata/SE 
11.0 (StataCorp, College Station, Tx USA). 
Observed/Predicted (O/P) EPO ratio was calculated 
in  order  to  determine  the  endogenouserythropoietin 
response to the level of Hb in our cohort of patients 
while at the same time avoiding possible interference 
by  the  endogenous  erythropoietin  production 
and/orerythropoietin activity. 
The O/P EPO ratio has been calculated by dividing 
the observedlog erythropoietin levels of the patients by 
the predicted log erythropoietin levelsto obtain the O/P 
ratio. The same ratio has been also calculated for the 
control group. 
Results: We estimated serum EPO levels in 55 normal 
healthy  controls  where  the  EPO  mean  was  7  mU/L 
(SD± 5.3). We observed that lymphoma patients had 
higher EPO levels compared with the healthy control 
group.  Hb  was  significantly  lower  in  lymphoma 
patients  compared with  the  control  group (P<0.001). 
Lymphoma  patients  had  significantly  higher  ferritin 
levels than the control group (P<0.001; Table 1). Also, 
Hb was lower in newly-diagnosed lymphoma patients 
when  compared  to  the  lymphoma  patients  in  the
chemotherapy group (P=0.003). EPO, LDH and ferritin 
concentrations  were  similar  for  newly-diagnosed 
lymphoma  patients  and  patients  who  underwent 
chemotherapy.  Stage  B  lymphoma  (symptomatic) 
patients comprised most of the lymphoma study group 
(73.9 %) compared with 19.6 % for stage A lymphoma 
(asymptomatic) and 6.5% for extranodal involvement 
patients. Stage A lymphoma patients had significantly 
higher  Hb  concentrations  compared  with  those  with 
stage  B  (P=0.028).  However,  EPO  levels  were  not 
significantly  higher  in  stage  B  lymphoma  patients 
compared with stage A patients (P=0.4), and there were 
no significant differences observed in LDH and ferritin 
levels between stage A and stage B lymphoma patients. 
There  was no statistical difference seen between HL 
and NHL patients in regard to EPO, Hb, ferritin, and 
LDH levels. 
Anemic patients accounted for 74.4% of the sample 
patients  while  non-anemic  patients  for  25.6%. There 
were  4  cases  who  had  severe  anemia  and  19  had 
moderate anemia  and 18 had mild anemia, while 14 
patients were not anemic.
Anemic  patients  had  higher  levels  of  EPO  than 
non-anemic  patients  or  healthy  controls  (P=0.001). 
However,  the  observed/predicted    EPO  ratio after 
adjustment  for  endogenous  EPO  response  from  the 
normal  EPO  production/activity  continue  to 
demonstrate  significantly  higher  levels  in  anemic 
lymphoma patients  versus  healthy controls (p=0.03) 
(Table  1).    There  were  significantly  higher  ferritin 
levels  in  non-anemic  lymphoma  patients  compared 
with  the  healthy control  group (P=0.015;  Figure  1). 
EPO, Hb and ferritin levels were significantly higher in 
non-anemic  lymphoma  patients  compared  to  healthy 
controls. 
Hb  levels  were  significantly  lower  in  “high  EPO 
group” compared to the “low-normal EPO group”. 
Discussion:  Our  analysis  showed  that  serum  EPO 
levels  were  higher  in  lymphoma  patients  compared 
with the healthy control group. This is most likely due 
to  EPO  response  to  anemia in  lymphoma  patients. 
Furthermore, anemic lymphoma patients (74.4%) had 
higher EPO levels compared to non-anemic lymphoma 
patients.  Similar  findings  have  been  reported  by 
Birgegård et al;
5 Li et al
12 and others.
18  Serum EPO 
concentrations  in  lymphoma  patients  exhibited  wide 
variation, ranging from normal levels to high levels in 
association  with  anemia.  Some  studies  showed  a 
decreased  level  of  EPO  in  treated  lymphoma
patients,
3,11,13 whereas the present study demonstrats no
Healthy controls Lymphoma patients Comparison
Normal range (N=55: Male 31) (N=54: Male 25)
Mean (SD) Mean (SD) Difference 95% CI P-value
Age (years) 43.6 (1.9) 40.7 (14.2) -2.9 (-6.8 to 1.0) 0.14
EPO level 
(mU/l)
3- 20 7.0 (5.3) 26.2 (25.8) 19.2 (12.2 to 26.2) <0.001
O/P  EPO 
ratio 1.70 (2.00) 1.04 (1.29) -0.66 (-1.29 to -0.04) 0.038
Hb (g/dl) 14-18 (male)
12-16 (female)
13.7 (1.4) 11.0 (1.9) -2.7 (-3.3 to -2.1) <0.001
Ferritin 
(ng/ml)
20- 300 43 (24) 627 (729) 583 (359 to 808) <0.001Mediterr J Hematol Infect Dis 2011, 3; Open Journal System
Figure 1. Distributions of non-anemic and anemic lymphoma patients compared with normal healthy controls
difference  in  EPO  levels  between  newly-diagnosed 
lymphoma patients and patients on chemotherapy. Our 
results are consistent with a previous study reported by 
Ozguroglu et al.
18 However, Lee
11 reported low levels 
of EPO in patients receiving chemotherapy compared 
with newly-diagnosed patients. An inverse relationship 
between Hb level and EPO was seen in our series in 
accordance  with  other  studies.
3,18 Furthermore,  the 
current study showed an improvement in Hb level in 
lymphoma  patients  treated  with  chemotherapy  for  at 
least three cycles as compared with patients who were 
newly-diagnosed (P=0.003). This is largely due to the 
fact  that  most  of  the  treated  patients  for  lymphoma 
disease were in advanced clinical stage III-IV (65%) 
that has responded with improvement of Hb secondary 
to  the  commenced  treatment.  Furthermore,  stage  A 
lymphoma patients had significantly higher initial Hb 
levels  compared  with  stage  B  patients  (P=0.028). 
Higher EPO levels were found in stage B patients in 
comparison  with  stage  A  but  was  not  statistically 
significant.  We  observed  higher  ferritin  levels  in 
lymphoma patients with high EPO levels compared to 
healthy controls (P<0.001), that has been explained by 
erythropoietic  response  to  anemia.  Therefore,  the 
ferritin level may indicate the increase of EPO activity 
among lymphoma patients. 
Conclusions:  In  summary,  an  adequate  EPO  and 
ferritin response to anemia in patients with lymphoma 
was demonstrated in our study. This may indicate that 
recombinant  human  EPO  (rhuEPO)  treatment  is  not 
required  in  anemic  lymphoma  patients  who  have 
acceptable EPO and ferritin response. Results obtained 
from this study would help in understanding different 
factors that contribute in the degree of anemia among 
lymphoma patients. Furthermore, most of the patients 
with  high  ferritin  levels  had  significantly  high  EPO 
levels. Perhaps more studies can address utilization of 
ferritin  as  a  possible  marker  for  EPO  activity  in 
addition to measuring the response to anemia in this 
cohort  of  patients.  Of  note,  the  cost  of  ferritin 
measurement  is  much  lower  than  that  of  EPO. 
Moreover, ferritin testing is  more accessible in most 
laboratories  compared  to  EPO.  However,  one  of  the 
important  limitations  is  that  ferritin  level  can  be 
affected as an acute phase reactant by the degree of 
infection  or  inflammation  that  may  coincide  in 
lymphoma patients. It is worth noting that we excluded 
all  patients  with  infections  from  the  current study. 
Nevertheless,  further  studies  to  confirm  our  findings 
are warranted. 
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